Ascelia has just concluded a call providing a commercial road-map following the positive SPARKLE results. Some of the takeaways include that we can expect Ascelia to re-activate earlier industrial discussions that could result in a commercial partnership and that the Company confirms that because of the positive SPARKLE results, it is in a much-improved situation to address the access to growth capital.

https://www.redeye.se/research/1004185/ascelia-pharma-some-feedback-from-the-sparkle-call?utm_source=finwire&utm_medium=RSS

Redeye